Quantcast
Last updated on April 18, 2014 at 0:06 EDT

Latest multiple sclerosis Stories

2013-01-31 12:28:04

GLEN ALLEN, Va., Jan. 31, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today announces publication of the first peer-reviewed article examining the effects of anatabine in a mouse model of the debilitating autoimmune and neurodegenerative disease multiple sclerosis (MS). The study, conducted by the Company's research partner, The Roskamp Institute, was designed to determine whether anatabine had beneficial effects on the development of experimental autoimmune encephalomyelitis...

2013-01-30 12:27:19

FORT LAUDERDALE, Fla., Jan. 30, 2013 /PRNewswire/ -- The Multiple Sclerosis Foundation's Cooling Program begins its 2013 cycle on February 1, helping those with multiple sclerosis (MS) to handle a troubling symptom of their disease: heat intolerance. For most people, heat and MS don't mix. As body temperature rises, weakness, fatigue, visual disturbances, and other symptoms can become aggravated and temporarily worsen. Without help, the hot summer months can trap those with MS indoors,...

2013-01-16 08:28:55

SEATTLE, Jan. 16, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its proprietary Cellular Redistribution Assay (CRA) technology, which to date has successfully "unlocked" 46 of the 80 total Class A orphan G Protein-Coupled Receptors (GPCRs) for drug development, has identified small molecules that interact with a Class B GPCR. Like the Class A GPCRs, Class B receptors are important players in a broad range of disorders, having been linked to various types of...

2013-01-16 08:24:44

EXTON, Penn., Jan. 16, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the recent commercial availability of Genzyme's Aubagio, the second oral disease-modifying agent (DMA) to the market following Novartis's launch of Gilenya in late 2010, is top of mind for few neurologists as a change in the management or treatment of their multiple sclerosis (MS) patients. Instead, data from the...

2013-01-09 08:26:36

EXTON, Pa., Jan. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that 16 percent of surveyed U.S. neurologists have initiated a trial of Genzyme's Aubagio, the second oral disease-modifying agent (DMA) to the multiple sclerosis (MS) market at one month post-launch, capturing less than one percent share among DMA-treated relapsing remitting MS patients. With Aubagio's oral administration...

2013-01-07 12:27:46

ROCHESTER, N.Y., Jan. 7, 2013 /PRNewswire/ -- Vaccinex, Inc. announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of therapeutic antibody candidate VX15/2503 in patients with multiple sclerosis. VX15/2503 is a novel humanized monoclonal antibody targeting the multi-functional protein semaphorin 4D (SEMA4D), and represents the second clinical trial for this investigational drug. Signaling cascades initiated by SEMA4D regulate...

2013-01-04 08:22:56

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine?1? phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC). Leading to the initiation of the RPC01-202 study, called TOUCHSTONE, Receptos successfully filed an Investigational New Drug (IND) Application...

2013-01-03 12:24:27

ROCKLAND, Mass. and NEW YORK, Jan. 3, 2013 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Rebif(®) Rebidose(®) (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). (Logo: http://photos.prnewswire.com/prnh/20130103/SF36310LOGO) (Logo:...

2013-01-03 08:26:50

TACOMA, Wash., Jan. 3, 2013 /PRNewswire/ -- Results from a collaborative project between Revalesio and Dr. Kalipada Pahan at Rush University showed remarkable therapeutic activity of Revalesio's novel therapeutic RNS60 in a mouse model of multiple sclerosis (MS). In a study recently published in the journal PLOS ONE, RNS60 halted disease progression (as measured by progressive limb paralysis), prevented inflammation in the brain and spinal column while also protecting against demyelination,...

2012-12-28 05:02:45

Part 1: Overview, progress toward stopping MS. New York, NY (PRWEB) December 27, 2012 MS research continued to advance on many fronts in 2012. This year saw:     The approval of a second oral therapy for relapsing forms of MS and other emerging treatments progressing through the development pipeline;     The launch of the International Progressive MS Collaborative, the largest effort to date to speed research to stop progressive forms of MS;...